Invesco Galaxy Bitcoin ETF vs Zimmer Biomet Holdings Inc — how do they compare? Invesco Galaxy Bitcoin ETF trades at $63.05, while Zimmer Biomet Holdings Inc trades at $96.37 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Invesco Galaxy Bitcoin ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BTCO | ZBH | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $125.14 | $107.71 |
52-Week Low | $58.40 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Trailing returns across standard periods
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →